Holen Sie sich die Stockscreener-App
12.52
4.29%
0.515
Schlusskurs vom Vortag:
$12.00
Offen:
$11.95
24-Stunden-Volumen:
297.04K
Relative Volume:
1.77
Marktkapitalisierung:
$575.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.28%
1M Leistung:
+39.06%
6M Leistung:
+73.58%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.56
$13.08
1-Wochen-Bereich:
$11.32
$13.21
52-Wochen-Spanne:
$6.565
$13.57
Jade Biosciences Inc Stock (JBIO) Company Profile
Firmenname
Jade Biosciences Inc
Sektor
Branche
Telefon
(781) 312-3013
Adresse
221 CRESCENT ST., WALTHAM
Vergleichen Sie JBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
12.52 | 552.05M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Eingeleitet | BTIG Research | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-05-07 | Eingeleitet | Wedbush | Outperform |
| 2025-05-05 | Eingeleitet | Stifel | Buy |
| 2025-05-02 | Eingeleitet | TD Cowen | Buy |
| 2024-06-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-06-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-03-25 | Fortgesetzt | Jefferies | Buy |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-12-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-08-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-07-26 | Eingeleitet | Cowen | Outperform |
| 2021-07-26 | Eingeleitet | Evercore ISI | Outperform |
| 2021-07-26 | Eingeleitet | Jefferies | Buy |
| 2021-07-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Jade Biosciences Inc Aktie (JBIO) Neueste Nachrichten
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect? - Zacks Investment Research
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives $19.75 Average Price Target from Brokerages - Defense World
Is Jade Biosciences Inc. stock resilient to inflationWeekly Trade Analysis & Daily Growth Stock Investment Tips - BỘ NỘI VỤ
Jade Biosciences Inc (JBIO) looking to reclaim success with recent performance - Setenews
Clear Street Initiates Coverage of Jade Biosciences (JBIO) with Buy Recommendation - Nasdaq
Clear Street initiates Jade Biosciences stock with Buy rating on IgAN therapy - Investing.com Canada
How Jade Biosciences Inc. stock performs after earnings2025 Top Gainers & High Win Rate Trade Tips - newser.com
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock - MSN
Guggenheim Maintains Jade Biosciences (JBIO) Buy Recommendation - MSN
Detecting support and resistance levels for Jade Biosciences Inc.Short Setup & Weekly High Conviction Trade Ideas - newser.com
How Jade Biosciences Inc. stock performs during Fed tightening cyclesJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Is Jade Biosciences Inc. forming a reversal patternJuly 2025 Analyst Calls & Proven Capital Preservation Methods - newser.com
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know - Zacks Investment Research
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
Does Jade Biosciences Inc. fit your quant trading modelWeekly Gains Report & Reliable Volume Spike Trade Alerts - newser.com
Jade Biosciences Advances Autoimmune Therapies - MSN
Multi asset correlation models including Jade Biosciences Inc.Quarterly Trade Review & Reliable Entry Point Alerts - newser.com
Jade Biosciences files for offering of up to 16.1 million shares of common stock by the selling stockholdersSEC filing - MarketScreener
Wedbush Adjusts Price Target on Jade Biosciences to $19 From $18, Maintains Outperform Rating - MarketScreener
JBIO: Strong pipeline progress and financing extend cash runway into 2028 despite higher net loss - TradingView
Jade Biosciences Reports Q3 2025 Financial Results - TipRanks
Jade Biosciences, Inc. SEC 10-Q Report - TradingView
How Jade Biosciences Inc. stock reacts to inflationary pressuresSell Signal & Daily Volume Surge Trade Alerts - newser.com
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Will Jade Biosciences Inc. see short term momentumWeekly Trend Summary & Safe Capital Growth Plans - newser.com
Jade Biosciences (JBIO) Price Target Increased by 13.43% to 19.38 - MSN
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 - The Manila Times
Jade Biosciences, Inc. Presents New Data Demonstrating A Favorable Preclinical Safety Profile of Jade101 and a Translational Analysis of April Mediated Biomarker Responses At the American Society of Nephrology Kidney Week 2025 - MarketScreener
Jade Biosciences (NASDAQ: JBIO) shows 55–68% IgA reductions in NHPs; JADE101 safety data - Stock Titan
Jade Biosciences Presents New Data Demonstrating a - GlobeNewswire
Jade Biosciences Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Finanzdaten der Jade Biosciences Inc-Aktie (JBIO)
Es liegen keine Finanzdaten für Jade Biosciences Inc (JBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):